We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00515944
Recruitment Status : Completed
First Posted : August 14, 2007
Last Update Posted : April 1, 2009
Sponsor:
Information provided by:

August 13, 2007
August 14, 2007
April 1, 2009
August 2007
February 2008   (Final data collection date for primary outcome measure)
Measurement of area
Same as current
Complete list of historical versions of study NCT00515944 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products
Not Provided
Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening. Botulinum toxin type A is used for certain neurological and aesthetic treatments. This study will investigate the migration potential of Xeomin®.
Conducted in Europe
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Healthy
Drug: Botulinum neurotoxin type A, free of complexing proteins
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
June 2008
February 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy females, 18 to 65 years
Sexes Eligible for Study: Female
18 Years to 65 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00515944
MRZ 60201-0709/1
Not Provided
Not Provided
Not Provided
Clinical Pharmacology, Merz Pharmaceuticals
Merz Pharmaceuticals GmbH
Not Provided
Study Chair: Merz Pharmaceuticals Merz Pharmaceuticals GmbH
Merz Pharmaceuticals GmbH
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP